相关实验视频
Updated: Jan 6, 2026

10:10
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
13.0K
在用多克索鲁比治疗癌症期间,在施用静止剂后保持认知功能:随机临床试验的二次分析
Pamela J Grizzard1, Nathaniel S O'Connell2, Stephen R Rapp3
1Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond.
JAMA network open
|October 21, 2025
概括
这项研究发现,在接受多克索鲁比化疗的癌症患者中,他类药物不会恶化认知功能. 然而,使用他类药物可能会改善执行功能,根据Trail Making Test的B部分进行测量.
科学领域:
- 在瘤学瘤学.
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 人环素化疗和他类药物的使用与癌症患者的认知能力下降有关.
- doxorubicin 是一种常见的 antracycline 化疗剂.
- 认知功能缺陷会影响癌症幸存者的生活质量.
研究的目的:
- 评估在接受多克索鲁比辛治疗的患者中,他类药物治疗和认知功能 (注意力,口语流,执行功能) 之间的关联.
- 为了确定他类药物是否减轻或加剧化疗引起的认知障碍.
主要方法:
- 一项随机临床试验的二次分析 (NCT01988571) 涉及238名淋巴瘤或乳腺癌患者.
- 参与者接受阿托瓦斯塔丁 (每天40毫克) 或安慰剂在多克索鲁比辛治疗前和治疗期间24个月.
- 认知功能使用Trail Making Test的A和B部分 (TMT-A,TMT-B) 和受控口语词汇协会测试进行评估.
主要成果:
- 在6个月和24个月后,他类药物和安慰剂组之间的TMT-A得分没有显著差异.
- 与安慰剂相比,在24个月内,静止剂接受者在TMT-B (执行功能) 中显著改善.
- 两个小组在口语流性方面表现出相似的改善 (控制口语词汇协会测试).
结论:
- 在多克索鲁比治疗癌症期间的他类药物治疗似乎不会恶化认知功能.
- 集团内部分析表明,他类药物可能为执行功能提供好处.
- 需要进一步的研究来证实他类药物在化疗患者中的神经保护作用.
相关概念视频
Cancer Survival Analysis
624
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
624
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Drug Dosing: Geriatric Patients
199
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199
Cancer Prevention
7.6K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
7.6K
Bioavailability Study Design: Healthy Subjects Versus Patients
126
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
126

